Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER_GOV 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2

Interventions

Azacitidine 4fludarabine 3venetoclax 2bisantrene 2Cyclophosphamide 2Clofarabine 2vosaroxin 1treosulfan 1liposomal amphotericin B 1defactinib 1decitabine and cedazuridine drug combination 1cedazuridine 1cc-486 1Thalidomide 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Interleukin-2 1Idarubicin 1Human Papillomavirus Recombinant Vaccine nonavalent 1Filgrastim 1Everolimus 1Dexamethasone 1Decitabine 1Daunorubicin 1Dasatinib 1Cytarabine 1Cyclosporine 1Control Groups 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Leukemia, Myeloid, Acute × bisantrene × Clear all
NCT04989335 2023-11-28

Bisantrene Combination for Resistant AML

Sheba Medical Center

Phase 2 Unknown
29 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03820908 2020-08-07

Bisantrene for Relapsed /Refractory AML

Sheba Medical Center

Phase 2 Completed
10 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡